Safety of erythrocyte encapsulated asparaginase in patients above 55 years of age newly diagnosed with acute lymphoblastic leukaemia.

Trial Profile

Safety of erythrocyte encapsulated asparaginase in patients above 55 years of age newly diagnosed with acute lymphoblastic leukaemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2014

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top